Intraoperative Tumor Margin Identification With ICG Dye Imaging

Recruiting now · Phase 2

Conditions studied: Benign Neoplasm, Malignant Neoplasm

In brief

In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in obtaining negative margins. Lastly, we want to assess traditional oncologic outcomes of local recurrence, time to metastatic disease, and overall and disease specific survival.

Key facts

Study ID

NCT04752137

Run by

Massachusetts General Hospital

People needed

100

Starts

2022-05-25

Expected to finish

2030-04-01

Last updated by the study team

2026-04-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients 18 years of age or older who present to Massachusetts General Hospital Department of Orthopaedic Surgery with a benign or malignant bone or soft tissue mass that is consented for surgery during the study period.

You may not qualify if…

• Pregnant or nursing patients
• Patients with previously known anaphylaxis to IV contrast or iodine (other allergies may be considered on a case-by-case basis)
• Patients in renal failure who are not cleared for ICG administration by their primary physician or oncologist

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.